Ophthalmic Disorders

First Gene Tx for Inherited Retinal Disease Gets Thumbs Up from FDA Committee

By October 13, 2017

The recommendation was based on data from the Luxturna clinical development program which included a Phase 3 trial in patients 4-44 years of age.

Glaucoma Treatments

October 13, 2017

Glaucoma treatment chart (alpha2-agonists, beta blockers, carbonic anhydrase inhibitors, cholinergic agonists, prostaglandin analogs).

Do Electronic Health Records Present Increased Burden on Ophthalmologists?

October 13, 2017

The researchers found that the mean total ophthalmologist examination time was 11.2 minutes per patient, of which 27% was spent on EHR use, 42% on conversation, and 31% on examination.

Combo Verteporfin Tx Assessed in Polypoidal Choroidal Vasculopathy

October 10, 2017

Mean improvement at 12 months was 8.3 letters with combination therapy compared with 5.1 letters with monotherapy, demonstrating that combination therapy met the predefined criterion for noninferiority as well as being superior to monotherapy.

Vancomycin-Associated HORV Prompts FDA Statement on Intraocular Use

By October 04, 2017

Although not FDA-approved, intraocular vancomycin is often used during cataract surgery to prevent postoperative endophthalmitis.

Infection Risk Investigated for Processed Tissue in Corneal Transplants

October 02, 2017

The researchers found that donor rim culture results were three times more likely to be positive for fungi in endothelial keratoplasty-processed eyes (1.14%) compared with other uses (0.37%).

Dietary Supplement Examined for Effects on Macular Pigment Density

September 29, 2017

The researchers found that there was a statistically significant increase in plasma lutein and zeaxanthin in the lutein plus zeaxanthin group after 3 months and 6 months of treatment versus the placebo group

Zika Associated with Similar Retinal Problems as Cobalamin C Deficiency

September 08, 2017

In 7 of 8 eyes with a normal photoreceptor layer, pericentral retina with normal lamination showed a thinned (<30% of normal thickness) ganglion cell layer (GCL) that colocalized.

USPSTF Issues Vision Screening Recommendation for Children

September 06, 2017

The USPSTF concluded that the overall net benefit is moderate for children aged 3 to 5 years (B recommendation).

Over-the-Counter Tx May Slow Age-Related Macular Degeneration

August 25, 2017

The investigators found that both formulations were cost-effective for treating patients with early-stage disease, but they were even more cost-effective for those with the condition in only 1 eye.

The Dos and Don'ts of Viewing a Solar Eclipse

By August 18, 2017

The moon passes the sun so quickly (at 2880km/h) that most of the time individuals (even those in the direct path of totality) will be experiencing a partial eclipse, and will be exposed to the sun's core.

FDA: Vision Impairment, Other Serious Side Effects Tied to Compounded Injectable

By July 31, 2017

The triamcinolone and moxifloxacin injection was intended for use as post-op prophylaxis for ocular inflammation and endophthalmitis to eliminate the use of post-op eye drops.

Eye Exams Should Be Requirement for Infants Potentially Exposed to Zika

July 18, 2017

One in 5 of the infants had sight-threatening eye abnormalities, with optic nerve and retinal abnormalities the most common.

Rohto Dry-Aid Now Available for Dry Eye Relief

By July 12, 2017

The micro-emulsion contains povidone 0.68% and propylene glycol 0.3%, which work by mimicking a natural tear to restore moisture to the tear film for up to 12 hours.

Early Biomarker May Help Differentiate Parkinsonism Disorders

July 12, 2017

Magnetic resonance imaging (T1-weighted and diffusion-weighted imaging) with a 3-T magnetic resonance imager revealed that the Parkinson's patients had significant alterations in optic radiation connectivity distribution.

Refresh Optive Mega-3 Available for Dry Eye Relief

By June 27, 2017

All Optive products have the patented osmoprotectant formula comprised of three solutes: glycerin, I-carnitine, and erythritol.

NDA Accepted for Anti-Inflammatory Inj Post-Cataract Surgery

By June 26, 2017

Dexycu injection was developed to help compliance—especially among elderly patients—and avoid dosing errors associated with conventional treatments that depend on self-administered eye drops multiple times a day.

Clinicians Overprescribing Antibiotics for Common Eye Infection

By June 19, 2017

Fifty-eight percent (n=198,462) of the total patients had filled ≥1 topical antibiotic prescription, of which approximately 20% (n=38,774) of patients filled prescriptions for combination antibiotic + corticosteroid products.

FDA Approves Zerviate for Allergic Conjunctivitis

By June 01, 2017

Zerviate is the first topical ocular formulation of cetirizine.

Roclatan Meets Primary Endpoint in Phase 3 Glaucoma Study

By May 24, 2017

The evaluation of Roclatan has been ongoing in two distinct trials.

Can Dietary Vitamin K Protect Against Cataracts?

May 22, 2017

After adjustment for potential confounders, the risk of cataracts was lower among participants in the highest versus the lowest tertile of dietary vitamin K1 intake (hazard ratio, 0.71).

FDA Accepts NDA for Glaucoma Drug Rhopressa

By May 15, 2017

The FDA has completed its initial 60-day review of the New Drug Application (NDA) for Rhopressa (netarsudil; Aerie) 0.02% and determined that it's sufficiently complete to permit a substantive review.

Implant Compared to Systemic Anti-inflammatory Therapy for Treating Uveitis

May 08, 2017

In seven-year follow-up, visual acuity better than with intravitreous fluocinolone acetonide implants

Teprotumumab for Thyroid-Associated Ophthalmopathy

By May 04, 2017

Smith, TJ et al. "Teprotumumab for Thyroid-Associated Ophthalmopathy". DOI: 10.1056/NEJMoa1614949.

Novel Therapy Shows Potential in Thyroid-Associated Ophthalmopathy

May 04, 2017

The researchers found that in the intention-to-treat population, 69 and 20% of those who received teprotumumab and placebo, respectively, had a response at week 24.

Anti-VEGF Treatments Examined for Effects on Diabetic Retinopathy

April 28, 2017

Researchers conducted a secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2mg), bevacizumab (1.25mg), or ranibizumab (0.3mg).

Treatment Combo Shows Promise for JIA-Associated Uveitis

April 27, 2017

Children with active JIA-associated uveitis who were taking a stable dose of methotrexate were randomly assigned to either adalimumab or placebo for 2 weeks.

Novel Tear Production Stimulator Given All Clear by FDA

By April 25, 2017

Safety and efficacy of the TrueTear device were demonstrated in two clinical studies in a total of 145 individuals with aqueous deficient dry eye.

Novel Therapy Shows Promise in Retinitis Pigmentosa

April 25, 2017

The researchers observed an increase in cone-like cells after switching rod to cone-like photoreceptors in situ by inactivation of Nrl or Nr2e3.

FDA Approves Treatment for All Forms of Diabetic Retinopathy

By April 17, 2017

The analysis indicated that patients with and without DME in the Lucentis treatment group had improvements in the severity of their retinopathy.